<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408252</url>
  </required_header>
  <id_info>
    <org_study_id>GORTEC 2006-01</org_study_id>
    <secondary_id>IIR Study A6181004</secondary_id>
    <nct_id>NCT00408252</nct_id>
  </id_info>
  <brief_title>Efficacy of SU 011248 in Head And Neck Carcinoma</brief_title>
  <official_title>A Phase II Study Of Su011248 In Patients With Recurrent And/Or Metastatic Squamous Head And Neck Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preclinical studies as well as phase I and II trials have demonstrated that SU11248 has&#xD;
      antitumor activity in renal cell carcinoma, breast cancer, neuroendocrine tumor and GIST. So&#xD;
      at the light of these pre-clinical and clinical data, it seems interesting and promising to&#xD;
      test SU011248 in these poor prognosis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label phase II, multicenter study. Eligible patients will receive SU011248 in&#xD;
      monotherapy (37.5 mg given continuously without interruption). Tumor check-up will be&#xD;
      performed every 6-8 weeks. Treatment will be continued until disease progression or&#xD;
      unacceptable toxicities according to the patient or the investigator (the median for&#xD;
      treatment in renal cell study was 8 months).&#xD;
&#xD;
      Since, head and neck tumors are easily accessible for iterative biopsy, this study will offer&#xD;
      the opportunity to get tumor biopsies before and after SU011248. Our study will allow&#xD;
      translational research with biopsies at crucial timing: at baseline before any treatment, ,&#xD;
      during the treatment with SU011248 (cycle 1, between week 4 and 6), for patients with stable&#xD;
      disease or partial response, a new biopsy will be performed at the time of disease&#xD;
      progression to try to understand the mechanisms of tumor or resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Too frequent grade 3-4 toxicities&#xD;
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the efficacy of SU011248 alone in patients with head and neck cancer in term of overall response rate (RECIST, see statistical consideration)</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety profile of SU011248 alone in patients with head and neck cancer.</measure>
    <time_frame>untill disaese progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the efficacy of SU011248 alone in patients with head and neck cancer: progression-free survival and survival.</measure>
    <time_frame>untill disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational research objective:To better understand the mechanisms of sunitinib resistance by the analysis of the tumor biopsies (RNA, gene expression profile) and protein profile (plasma samples). Exploratory analyses.</measure>
    <time_frame>at week 6 and at disaese progression after recist response</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Recurrent Disease</condition>
  <condition>Squamous Cell Head and Neck Carcinoma</condition>
  <condition>Palliative Treatment</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive SU011248 in monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biopsies</intervention_name>
    <description>No intervention, only biopsy for translational project</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU011248</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recurrent and/or metastatic head and neck squamous cell carcinoma not amenable to&#xD;
             curative treatment with surgery and/or chemotherapy and/or radiation&#xD;
&#xD;
          -  Recurrence must be confirmed by anatomopathology (cytology or biopsy)&#xD;
&#xD;
          -  At least one measurable lesion by MRI or CT-scan&#xD;
&#xD;
          -  Failed or relapsing after first line chemotherapy including a platinum* or a&#xD;
             taxane-based chemotherapy regimen&#xD;
&#xD;
          -  Patients ineligible for chemotherapy could be included in first line&#xD;
&#xD;
          -  ECOG performance status 0 -2, in stable medical condition&#xD;
&#xD;
          -  Patients must be able to swallow tablets&#xD;
&#xD;
          -  Patients must have an expected survival of at least 3 months&#xD;
&#xD;
          -  Paraffin-embedded tumor tissue available for immunohistochemistry&#xD;
&#xD;
          -  Patients must be over 18 years old and must be able to give written informed consent&#xD;
&#xD;
          -  Women of child-bearing age must have a negative pregnancy test&#xD;
&#xD;
          -  Female patients of child-bearing age must use effective contraception until 3 months&#xD;
             have elapsed after the last injection&#xD;
&#xD;
          -  Patients must have normal organ function&#xD;
&#xD;
          -  For patients with local recurrence and easily accessible tumors, acceptance of&#xD;
             iterative biopsies to store tumor samples (Formaldehyde for immunochemistry, RNA&#xD;
             later)&#xD;
&#xD;
          -  Acceptance of giving 20 ml of blood for eventual pharmacogenomic analysis&#xD;
&#xD;
          -  Acceptance of giving two plasma samples (3ml) at baseline and after 4 weeks of&#xD;
             treatment with SU011248&#xD;
&#xD;
          -  Signed informed consent prior to beginning protocol specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-squamous head and neck cancer&#xD;
&#xD;
          -  Nasopharynx cancer&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  More than two lines of chemotherapy for palliative treatment (except if chemotherapy&#xD;
             was given as a part of a multimodal treatment given with a curative intent)&#xD;
&#xD;
          -  Surgery or irradiation or investigational drugs within 4 weeks before study inclusion&#xD;
&#xD;
          -  Other uncontrolled illnesses (active infections requiring antibiotics, bleeding&#xD;
             disorders, …)&#xD;
&#xD;
          -  Active uncontrolled coronary disease or cardiac insufficiency (Ejection fraction below&#xD;
             40%)&#xD;
&#xD;
          -  Previous malignancy, with exception of a history of a previous basal cell carcinoma of&#xD;
             the skin or pre-invasive carcinoma of the cervix&#xD;
&#xD;
          -  Other concomitant anticancer therapies&#xD;
&#xD;
          -  Previous treatment with anti-VEGF, PDGF, or kit therapies. EGFR therapy is not an&#xD;
             exclusion criteria.&#xD;
&#xD;
          -  Organic brain syndrome or significant psychiatric abnormality that would preclude&#xD;
             participation in the full protocol and follow up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal H Machiels, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universiatires St LUC UCL</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>clinique Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique universiataire de Mont Godinnes UCL</name>
      <address>
        <city>Yvoir</city>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>263011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre G-f Leclerc</name>
      <address>
        <city>DIJON Cedex</city>
        <zip>8021079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>4511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>René Gauducheau</name>
      <address>
        <city>Saint Herblain Cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours cedex 1</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 4, 2006</study_first_submitted>
  <study_first_submitted_qc>December 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2006</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent or locally advanced</keyword>
  <keyword>cytokine failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

